company background image
ILMN

Illumina NasdaqGS:ILMN Stock Report

Last Price

US$218.08

Market Cap

US$34.3b

7D

-1.8%

1Y

-39.0%

Updated

30 Nov, 2022

Data

Company Financials +
ILMN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ILMN Stock Overview

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis.

Rewards

Trading at 39.2% below our estimate of its fair value

Earnings are forecast to grow 74.96% per year

Risk Analysis

No risks detected for ILMN from our risk checks.

Illumina, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Illumina
Historical stock prices
Current Share PriceUS$218.08
52 Week HighUS$428.00
52 Week LowUS$173.45
Beta1.17
1 Month Change-4.69%
3 Month Change8.70%
1 Year Change-39.03%
3 Year Change-31.78%
5 Year Change1.92%
Change since IPO1,013.45%

Recent News & Updates

These 4 Measures Indicate That Illumina (NASDAQ:ILMN) Is Using Debt Reasonably Well

Oct 27
These 4 Measures Indicate That Illumina (NASDAQ:ILMN) Is Using Debt Reasonably Well

Illumina, GenoScreen collaborate on genomic testing for drug-resistant TB

Oct 18

Recent updates

These 4 Measures Indicate That Illumina (NASDAQ:ILMN) Is Using Debt Reasonably Well

Oct 27
These 4 Measures Indicate That Illumina (NASDAQ:ILMN) Is Using Debt Reasonably Well

Is It Too Late To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Aug 08
Is It Too Late To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Is Illumina, Inc. (NASDAQ:ILMN) Trading At A 48% Discount?

Jul 22
Is Illumina, Inc. (NASDAQ:ILMN) Trading At A 48% Discount?

Does Illumina (NASDAQ:ILMN) Have A Healthy Balance Sheet?

Jun 14
Does Illumina (NASDAQ:ILMN) Have A Healthy Balance Sheet?

Is There Now An Opportunity In Illumina, Inc. (NASDAQ:ILMN)?

May 09
Is There Now An Opportunity In Illumina, Inc. (NASDAQ:ILMN)?

An Intrinsic Calculation For Illumina, Inc. (NASDAQ:ILMN) Suggests It's 44% Undervalued

Apr 21
An Intrinsic Calculation For Illumina, Inc. (NASDAQ:ILMN) Suggests It's 44% Undervalued

Is Illumina (NASDAQ:ILMN) Using Too Much Debt?

Mar 05
Is Illumina (NASDAQ:ILMN) Using Too Much Debt?

What Does Illumina, Inc.'s (NASDAQ:ILMN) Share Price Indicate?

Feb 03
What Does Illumina, Inc.'s (NASDAQ:ILMN) Share Price Indicate?

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 31% Undervaluation?

Jan 21
Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 31% Undervaluation?

Is Illumina (NASDAQ:ILMN) Using Too Much Debt?

Nov 30
Is Illumina (NASDAQ:ILMN) Using Too Much Debt?

What Does Illumina, Inc.'s (NASDAQ:ILMN) Share Price Indicate?

Nov 04
What Does Illumina, Inc.'s (NASDAQ:ILMN) Share Price Indicate?

Are Investors Undervaluing Illumina, Inc. (NASDAQ:ILMN) By 50%?

Oct 17
Are Investors Undervaluing Illumina, Inc. (NASDAQ:ILMN) By 50%?

Illumina (NASDAQ:ILMN) Has A Pretty Healthy Balance Sheet

Aug 17
Illumina (NASDAQ:ILMN) Has A Pretty Healthy Balance Sheet

These 4 Measures Indicate That Illumina (NASDAQ:ILMN) Is Using Debt Reasonably Well

May 04
These 4 Measures Indicate That Illumina (NASDAQ:ILMN) Is Using Debt Reasonably Well

Shareholder Returns

ILMNUS Life SciencesUS Market
7D-1.8%1.9%1.5%
1Y-39.0%-26.1%-14.8%

Return vs Industry: ILMN underperformed the US Life Sciences industry which returned -26.1% over the past year.

Return vs Market: ILMN underperformed the US Market which returned -14.8% over the past year.

Price Volatility

Is ILMN's price volatile compared to industry and market?
ILMN volatility
ILMN Average Weekly Movement7.5%
Life Sciences Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: ILMN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: ILMN's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19989,825Francis deSouzahttps://www.illumina.com

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services.

Illumina, Inc. Fundamentals Summary

How do Illumina's earnings and revenue compare to its market cap?
ILMN fundamental statistics
Market CapUS$34.30b
Earnings (TTM)-US$4.15b
Revenue (TTM)US$4.70b

7.3x

P/S Ratio

-8.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ILMN income statement (TTM)
RevenueUS$4.70b
Cost of RevenueUS$1.42b
Gross ProfitUS$3.28b
Other ExpensesUS$7.44b
Earnings-US$4.15b

Last Reported Earnings

Oct 02, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-26.40
Gross Margin69.83%
Net Profit Margin-88.36%
Debt/Equity Ratio25.9%

How did ILMN perform over the long term?

See historical performance and comparison